Document:

Careview Communications, Inc. 8-K

EXHIBIT
10.26

 

Exhibit
D-1

 

AMENDED AND
RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This
Amended and Restated Intellectual Property Security Agreement is entered into as of __________, 2015 by and among HealthCor
Partners Fund, L.P., a Delaware limited partnership with a principal office located at Carnegie Hall Towers, 152 West 57th
Street, New York, NY 10019 (“HealthCor Partners”), as collateral agent (“Agent”), CareView
Communications, Inc., a Nevada corporation with a principal office located at 405 State Highway 121, Suite B-240, Lewisville,
TX 75067 (“CareView NV”), CareView Communications, Inc., a Texas corporation with a principal office
located at 405 State Highway 121, Suite B-240, Lewisville, TX 75067 (“CareView TX”) and CareView Operations,
LLC, a Texas limited liability company with a principal office located at 405 State Highway 121, Suite B-240, Lewisville,
TX 75067 (“CareView LLC” and together with CareView TX and CareView NV, collectively referred to herein as
the “Grantor”).

 

RECITALS

 

A.CareView
NV, HealthCor Partners and HealthCor Hybrid Offshore Master Fund, L.P., a Cayman Islands limited partnership (“HealthCor
Offshore”), entered into that certain Note and Warrant Purchase Agreement dated as of April 21, 2011 (as amended prior
to the date hereof, the “Original Purchase Agreement”);

B.In
connection with the purchase of Notes under the Original Purchase Agreement, the Grantor entered into that certain Pledge and
Security Agreement dated as of April 21, 2011 in favor of HealthCor Partners and HealthCor Offshore, as secured parties (as amended
prior to the date hereof, the “Original Security Agreement”).

C.As
of the date hereof, HealthCor Partners and certain additional investors are purchasing additional Notes in the aggregate amount
pursuant to that certain Fifth Amendment to Note and Warrant Agreement, which amends that certain Note and Warrant Purchase Agreement
dated as of April 21, 2011 (as amended, restated or otherwise modified from time to time, the “Purchase Agreement”)
by and among CareView NV and the Investors party thereto;

D.The
Secured Parties (as defined in the Security Agreement) are willing to purchase the Notes and make such cash advance to CareView
NV, but only upon the condition, among others, that the Grantor shall grant to Agent for the benefit of the Secured Parties a
security interest in its Copyrights, Trademarks, Patents, and Mask Works (as each term is defined below) to secure the Obligations
(as defined in the Security Agreement (as defined below)) under the Purchase Agreement and the Transaction Documents.

C.Pursuant
to the terms of the Purchase Agreement and that certain Amended and Restated Pledge and Security Agreement by and among Agent,
the Secured Parties and the Grantor, of even date herewith (as the same may be amended, modified or supplemented from time to
time, the “Security Agreement”), the Grantor has granted to Agent for the ratable benefit of the Secured Parties
a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in,
to and under all of the Collateral.

NOW,
THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as
collateral security for the prompt and complete payment when due of its Obligations under the Purchase Agreement and the Transaction
Documents, the Grantor hereby represents, warrants, covenants and agrees as follows:

 

    	

    	 

    

 

AGREEMENT

 

To
secure CareView NV’s Obligations under the Purchase Agreement and the Transaction Documents, the Grantor grants and pledges
to Agent for the ratable benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest
in, to and under the Grantor’s intellectual property (all of which shall collectively
be called the “Intellectual Property Collateral”), including, without limitation, the following:

1.Any
and all right, title, and interest in and to the following: (a) all copyrights, rights and interests in copyrights, works protectable
by copyright, copyright registrations, and copyright applications; (b) all renewals of any of the foregoing; (c) all income, royalties,
damages, and payments now or hereafter due and/or payable under any of the foregoing, including, without limitation, damages or
payments for past or future infringements for any of the foregoing; (d) the right to sue for past, present, and future infringements
of any of the foregoing; and (e) all rights corresponding to any of the foregoing throughout the world, whether now or hereafter
existing, created, acquired or held, and including without limitation those set forth on Exhibit A attached hereto (collectively,
the “Copyrights”);

2.Any
and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or
hereafter existing, created, acquired or held;

3.Any
and all design rights that may be available to the Grantor now or that may hereafter be existing, created, acquired or held;

4.Any
and all right, title, and interest in and to: (a) any and all patents and patent applications;
(b) all inventions and improvements described and claimed therein; (c) all reissues, divisions, continuations, renewals, extensions,
and continuations-in-part thereof; (d) all income, royalties, damages, claims, and payments now or hereafter due or payable under
and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (e) all
rights to sue for past, present, and future infringements thereof; and (f) all rights corresponding to any of the foregoing throughout
the world, whether now or hereafter existing, created, acquired or held, and including without
limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

5.Any
and all right, title, and interest in and to the following: (a) all trademarks (including service marks), trade names,
trade dress, and trade styles and the registrations and applications for registration thereof and the goodwill of the business
symbolized by the foregoing; (b) all licenses of the foregoing, whether as licensee or licensor; (c) all renewals of the foregoing;
(d) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation,
damages, claims, and payments for past and future infringements thereof; (e) all rights to sue for past, present, and future infringements
of the foregoing, including the right to settle suits involving claims and demands for royalties owing; and (f) all rights corresponding
to any of the foregoing throughout the world, whether now or hereafter existing, created,
acquired or held, and including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

6.All
mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including,
without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

7.Any
and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right,
but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified
above;

 

    	2

    	 

    

 

8.All
licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising
from such use to the extent permitted by such license or rights;

9.All
amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

10.All
proceeds and products of the foregoing, including, without limitation, all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing.

This
security interest is granted in conjunction with the security interest granted to Agent for the benefit of the Secured Parties
under the Purchase Agreement and the Security Agreement. The rights and remedies of Agent with respect to the security interest
granted hereby are in addition to those set forth in the Purchase Agreement, the Security Agreement and the other Transaction
Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy
of Agent provided for herein or in the Purchase Agreement, the Security Agreement or any of the other Transaction Documents, or
now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power
or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this
Intellectual Property Security Agreement, the Purchase Agreement, the Security Agreement or any of the other Transaction Documents,
or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including
Agent, of any or all other rights, powers or remedies. This agreement amends and restates in its entirety that certain Intellectual
Property Security Agreement dated as of April 21, 2011 by and among the Secured Parties and Grantor.

 

[Signature page
follows.]

 

 

    	3

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto
duly authorized as of the first date written above.

 

	 	GRANTOR:
	 	 
	Address of Grantor:	CAREVIEW COMMUNICATIONS, INC., a Nevada corporation
	 	 
	405 State Highway 121	By:_______________________________
	Suite B-240	Name:_____________________________
	Lewisville, TX 75067	Title:__________________________
	Attn: Steven Johnson	 

 

 

		CAREVIEW COMMUNICATIONS, INC., a Texas corporation
	 	 
	405 State Highway 121	By:_______________________________
	Suite B-240	Name:_____________________________
	Lewisville, TX 75067	Title:______________________________
	Attn: Steven Johnson	 

 

 

		CAREVIEW OPERATIONS, LLC
	 	 
	405 State Highway 121	By:_______________________________
	Suite B-240	Name:_____________________________
	Lewisville, TX 75067	Title:______________________________
	Attn: Steven Johnson	 

 

 

	 	AGENT:
	 	 
	Address of Agent:	HEALTHCOR PARTNERS FUND, L.P.
	 	 
	 	By: HealthCor Partners Management, G.P., LLC, as Manager
	 	 
	 	By: HealthCor Partners Management, G.P., LLC, as General Partner
	 	 
	HealthCor Partners	 
	Carnegie Hall Towers	By:_______________________________
	152 West 57th Street	Name: Jeffrey C. Lightcap
	New York, NY 10019	Title: Senior Managing Director

 

    	 

    	 

    

 

 

	 	Consented to and agreed by:
	 	 
		HEALTHCOR
HYBRID OFFSHORE MASTER FUND, L.P.
	 	 
	 	By: HealthCor Hybrid Offshore G.P., LLC, as General
    Partner
	 	 
		By:_______________________________
		Name: 
		Title:EX-10.1

 Exhibit 10.1 

SUBSCRIPTION AND INVESTMENT AGREEMENT 

This Subscription and Investment Agreement (this “Agreement”) is dated as of December 18, 2014, between Conkwest, Inc.,
a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this
Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: 

ARTICLE I. 
 DEFINITIONS

 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth
in this Section 1.1: 
 “Affiliate” means any Person that, directly or indirectly through one or
more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. 

“Board of Directors” means the board of directors of the Company. 

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the
United States or any day on which banking institutions in the State of California are authorized or required by law or other governmental action to close. 

“Closing” means each of the Initial Closing and each Additional Closing of the purchase and sale of the
Securities pursuant to Section 2.1. 
 “Commission” means the United States Securities and
Exchange Commission. 
 “Common Stock” means the Class A common stock of the Company, par value $0.0001
per share, and any other class of securities into which such securities may hereafter be reclassified or changed. 

“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the
holder thereof to acquire at any time Common Stock, including, without limitation, any indebtedness, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock. 

 “Company Counsel” means Greenberg Traurig, LLP with offices
located at the MetLife Building, 200 Park Avenue, New York, New York 10166. 
 “Disclosure Schedules” shall
have the meaning ascribed to such term in Section 3.1. 
 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “FCPA” means the
Foreign Corrupt Practices Act of 1977, as amended. 
 “JV Documents” means the definitive agreements documenting
the joint development and license arrangement between the Company and Sorrento Therapeutics, Inc. 

“Licenses” shall mean the licenses and/or sublicenses, as the case may be, identified in the attached
Schedule 3.1(p). 
 “Liens” means a lien, charge, pledge, security interest, encumbrance,
right of first refusal, preemptive right or other restriction. 
 “Patents” shall mean the letters patent
and pending patent applications identified more fully in the attached Schedule 3.1(p), and shall also include the following: 

1. Any divisional, continuation, reissue, or substitute patent or patent application and extensions of such patent or patent
application, that shall be based on any of the above-described patents or patent applications; 
 2. Any patents that issue
from any of the above-described patent applications; and 
 3. Patents and patent applications corresponding to each of the
above-described patents or patent applications that are issued, filed, or to be filed in any and all countries; any patents (including but not limited to patents of importation or addition, utility models, and inventor certificates) that shall
subsequently issue thereof; and any renewals, divisions, reissues, continuations, or extensions thereof. 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

  
 2 

 “Proceeding” means an action, claim, suit, investigation or
proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Qualified IPO” means a firm commitment underwritten initial public offering of Common Stock pursuant to an
effective registration statement on file with the Commission. 
 “Registration Rights Agreement” means the
Registration Rights Agreement, to be entered into among the Company and the Purchasers in connection with the Second Additional Closing, in the form of Exhibit A attached hereto. 

“Registration Statement” means a registration statement covering the issuance or resale of the Common Stock by
each Purchaser. 
 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act,
as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 

“Securities” means the shares of Common Stock to be purchased by the Purchasers pursuant to this Agreement.

 “Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for the shares of
Common Stock purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available funds. 

“Subsidiary” means any subsidiary of the Company as set forth on Schedule 3.1(a) and shall, where
applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. 

“Trademarks” shall mean the registrations or pending applications for the trademarks or service marks
identified in the attached Schedule 3.1(p). 
 “Trading Day” means a day on which the principal
Trading Market is open for trading. 

  
 3 

 “Trading Market” means any of the following markets or exchanges
on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQX, OTCQB, or the OTC Bulletin
Board (or any successors to any of the foregoing). 
 “Transaction Documents” means this Agreement, the
Registration Rights Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder or thereunder. 

“Transfer Agent” means the current transfer agent of the Company, and any successor transfer agent of the
Company. In the absence of another Transfer Agent, the Transfer Agent shall be the Company. 
 ARTICLE II. 

PURCHASE AND SALE 
 2.1
Closing. On each Closing Date (as defined below), upon the terms and subject to the conditions set forth herein, and in the case of the Initial Closing substantially concurrent with the execution and delivery of this Agreement by the parties
hereto, the Company agrees to sell, and each Purchaser agrees, severally and not jointly, to purchase shares of Common Stock for the aggregate Subscription Amount specified below the Purchaser’s name on the signature pages of this Agreement and
next to the heading “Subscription Amount” for such Closing Date. Each Purchaser shall deliver to the Company, via wire transfer, immediately available funds equal to such Purchaser’s Subscription Amount for such Closing Date as set
forth on the signature page hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective shares of Common Stock as determined pursuant to Section 2.2(a) or 2.2(c), as applicable, and the
Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at such Closing. Upon satisfaction of the covenants and conditions set forth in Section 2.3, each Closing shall occur at the
offices of Company Counsel or such other location as the parties shall mutually agree. 
 (a) Initial Closing. The date and time of
the Initial Closing (the “Initial Closing Date”) shall be 10:00 a.m. (California time), on the first (1st) Trading Day (and including the date hereof if a Trading Day) on
which the applicable conditions to the Initial Closing set forth in Section 2.3 below are satisfied or waived. 
 (b)
Additional Closing. Subject to the satisfaction (or, where legally permissible, the waiver) of the applicable conditions set forth in Section 2.3 below, solely with respect to each Purchaser that elects on the signature page of
such Purchaser hereto to participate in one or more additional closings (each, an “Additional Closing”, and any such Purchasers, each an “Additional Purchaser”), each Additional Purchaser shall purchase such
aggregate number of additional shares of Common Stock as set forth on the signature page executed by such Additional Purchaser with 

  
 4 

 
respect to the following Additional Closings (each, an “Additional Closing Date”, and together with the Initial Closing Date, each a “Closing Date”), as
applicable: (A) the date of execution of the JV Documents (the “First Additional Closing Date”) and/or (B) the date designated by the Company in a written notice to each such Purchaser delivered no less than three
(3) Business Days prior to the consummation of a Qualified IPO (the “Second Additional Closing Date”). 
 2.2
Deliveries. 
 (a) On or prior to the Initial Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the
following: 
 (i) this Agreement duly executed by the Company; 

(ii) a Common Stock certificate registered in the name of such Purchaser for a number of shares of Common Stock equal to such
Purchaser’s Subscription Amount divided by $3.25; and 
 (iii) the Registration Rights Agreement duly executed by the Company. 

(b) On or prior to the Initial Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: 

(i) this Agreement duly executed by such Purchaser; 

(ii) such Purchaser’s Subscription Amount for the Common Stock by wire transfer to the account specified in writing by the Company; and

 (iii) the Registration Rights Agreement duly executed by such Purchaser. 

(c) On or prior to the First Additional Closing Date, the Company shall deliver or cause to be delivered to each participating Additional
Purchaser a Common Stock certificate registered in the name of such Additional Purchaser for a number of shares of Common Stock equal to such Additional Purchaser’s Subscription Amount divided by $3.25. 

(d) On or prior to the First Additional Closing Date, each participating Additional Purchaser shall deliver or cause to be delivered to the
Company such Additional Purchaser’s Subscription Amount for the Common Stock by wire transfer to the account specified in writing by the Company. 

(e) On or prior to the Second Additional Closing Date, the Company shall deliver or cause to be delivered to each participating Additional
Purchaser a Common Stock certificate registered in the name of such Additional Purchaser for a number of shares of Common Stock equal to such Additional Purchaser’s Subscription Amount divided by the public offering price per share of Common
Stock in the Qualified IPO. 

  
 5 

 (f) On or prior to the Second Additional Closing Date, each participating Additional Purchaser
shall deliver or cause to be delivered to the Company such Additional Purchaser’s Subscription Amount for the Common Stock by wire transfer to the account specified in writing by the Company. 

2.3 Closing Conditions. 

(a) The obligations of the Company hereunder in connection with each Closing are subject to the following conditions being met: 

(i) the accuracy in all material respects on the applicable Closing Date of the representations and warranties of the applicable Purchasers
contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects as of such date); 

(ii) all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the applicable Closing Date shall
have been performed; and 
 (iii) the delivery by each applicable Purchaser of the items set forth in Section 2.2(b) or 2.2
(d) of this Agreement, as applicable. 
 (b) The respective obligations of each Purchaser hereunder in connection with each Closing
in which such Purchaser is participating hereunder are subject to the following conditions being met: 
 (i) the accuracy in all material
respects when made and on the applicable Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects as of such date); 

(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall have
been performed; 
 (iii) the delivery by the Company of the items set forth in Section 2.2(a) and 2.2 (c) of this
Agreement, as applicable; 
 (iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; 

(v) the delivery to the Purchasers of an officers’ certificate of the Company’s Chief Executive Officer and Chief Financial
Officer, confirming that the conditions specified in Sections 2.3(b)(i) and (ii) above have been fulfilled; 
 (vi) the delivery to
the Purchasers of a certificate from the Company’s Secretary, attaching thereto (i) the Company’s Certificate of Incorporation as in effect at the time 

  
 6 

 
of the Closing, (ii) the Company’s Bylaws as in effect at the time of the Closing, (iii) resolutions approved by the Board authorizing the transactions contemplated hereby, and
(iv) good standing certificates (including tax good standing) with respect to the Company from the applicable authority(ies) in Delaware and any other jurisdiction in which the Company is qualified to do business, dated no more than three
business days prior to the Closing Date; 
 (vii) the sale and issuance of the Securities is legally permitted by all laws and regulations
to which the Purchasers and the Company are subject on the applicable Closing Date; 
 (viii) any and all consents, permits and waivers
necessary or appropriate for consummation of the transactions contemplated by this Agreement and the Related Agreements except for such as may be properly obtained subsequent to the applicable Closing, shall have been obtained by the Company; and

 (ix) all corporate and other proceedings in connection with the transactions contemplated at the applicable Closing and all documents
incident thereto shall be reasonably satisfactory in form and substance to the Purchasers, and the Purchasers (or their counsel) shall have received all such counterpart original and certified or other copies of such documents as reasonably
requested. 
 ARTICLE III. 

REPRESENTATIONS AND WARRANTIES 

3.1 Representations and Warranties of the Company. Except as set forth in the schedules delivered to the Purchasers of the date hereof
(the “Disclosure Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosure contained in the corresponding section of the Disclosure
Schedules, the Company hereby makes the following representations and warranties to each Purchaser as of the date hereof, and as of each Closing Date with respect to such Purchasers participating in such Closing: 

(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company owns,
directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded. 

(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.

  
 7 

 
Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter
documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it
makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a
material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no
Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 

(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the
Company’s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed
by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 

(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not, subject in each case to the Required Approvals: (i) conflict with or violate any
provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with or without notice, lapse
of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any

  
 8 

 
Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the
Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 

(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents,
other than: (i) following the Second Additional Closing Date, the filing with the Commission of a Registration Statement pursuant to the Registration Rights Agreement and in accordance with the terms thereof, (ii) the notice and/or
application(s) to each applicable Trading Market for the issuance and sale of the Securities, and (iii) the filing of a Form D with the Commission and such filings as are required to be made under applicable state securities laws. 

(f) Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. 

(g) Registration Rights. Except as provided in the Registration Rights Agreement or as set forth on Schedule 3.1(g), no Person
has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company or any Subsidiaries. 

(h) Capitalization. The capitalization of the Company is as set forth on Schedule 3.1(h), which Schedule 3.1(h) shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. Except as set forth on Schedule 3.1(h), no Person has any right of first refusal, preemptive right, right
of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on Schedule 3.1(h), except as a result of the purchase and sale of the Securities, there are no
outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents.
Except as set forth on Schedule 3.1(h), the issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any
holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all federal and state securities 

  
 9 

 
laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Other than the Required Approvals, no further
approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except as set forth on Schedule 3.1(h), there are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 

(i) Financial Statements. The audited financial statements of the Company for the years ended December 31, 2012 and 2013 and the
unaudited financial statements for the nine-month period ended September 30, 2014 are attached hereto as Schedule 3.1(i). Such financial statements have been prepared in accordance with United States generally accepted accounting
principles (“GAAP”) applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that the quarterly financial statements may not contain all
footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject to normal, immaterial, year-end audit adjustments. 
 (j) Material Changes; Undisclosed Events, Liabilities or Developments.
Except as set forth on Schedule 3.1(j), since the date of the latest financial statements attached as Schedule 3.1(i): (i) there has been no event, occurrence or development that has had or that could reasonably be expected to
result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP, (iii) the Company has not altered its method of accounting or the manner in which it keeps its accounting books and records,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans, consulting agreements or employment agreements approved by the Board of Directors. 

(k) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the
Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse Effect. 
 (l) Labor Relations. No labor dispute exists or, to the
knowledge of the Company, is imminent with respect to any of the employees of the Company or any of its Subsidiaries, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its

  
 10 

 
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a
party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. 

(m) Compliance. Neither the Company nor any Subsidiary: (i), is in default under or in violation of (and no event has occurred that has
not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation
of any judgment, decree or order of any court, arbitrator or other governmental authority, or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all
foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to
result in a Material Adverse Effect. 
 (n) Regulatory Permits. The Company and the Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such permits could not reasonably be expected to
result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit. 

(o) Title to Assets. The Company and the Subsidiaries have good and marketable title in all personal property owned by them that is
material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable
leases with which the Company and the Subsidiaries are in compliance in all material respects. 
 (p) Intellectual Property. The
Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, and other proprietary rights and processes necessary for its business as now conducted and as
presently proposed to be conducted, without any infringement of the rights of others (or with respect to patents, any known infringement of the rights of others). There are no outstanding options, licenses, or agreements of any kind relating to the
foregoing proprietary rights other than options for use of proprietary rights for academic research only with no commercial use, and license agreements with Inex Bio and Intrexon, Inc., nor is the Company bound by or a party to any options,
licenses, or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, and other proprietary rights and processes of any other person or entity other than such
licenses or agreements arising from the purchase of “off the shelf” or standard products, and other than the license agreement with Fox 

  
 11 

 
Chase Cancer Research Center related to patented and proprietary property. The Company has not received any communications alleging that the Company has violated or, by conducting its business as
presently proposed to be conducted, would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, or other proprietary rights of any other person or entity, nor is the Company aware of any basis therefor. The
Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree, or order of any court or administrative agency, that
would interfere with their duties to the Company or that would conflict with the Company’s business as proposed to be conducted. Each former and current employee, officer, and consultant of the Company has executed a proprietary information and
inventions agreement on the Company’s standard form thereof (collectively, the “PIIA”). No former or current employee, officer or consultant of the Company has excluded works or inventions made prior to his or her employment with the
Company from his or her assignment of inventions related to the business of the Company pursuant to such employee, officer, or consultant’s proprietary information and inventions agreement. The Company does not believe it is or will be
necessary to utilize any inventions, trade secrets, or proprietary information of any of its employees made prior to their employment by the Company, except for inventions, trade secrets, or proprietary information that have been assigned to the
Company. Neither the Company, the Company’s products, nor any software or technology developed by or for the Company is subject to any obligation or condition that would require that any of the Company’s products or any other software or
other technology developed by or for the Company (i) be disclosed, distributed, or made available in source code form; (ii) be licensed with the permission to create derivative works; or (iii) be redistributable at no charge. 

(q) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage for a privately owned company in the businesses
in which the Company and Subsidiaries are engaged. 
 (r) Certain Fees. No brokerage or finder’s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers
shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction
Documents. 
 (s) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby. 

(t) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an 

  
 12 

 
“investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an
“investment company” subject to registration under the Investment Company Act of 1940, as amended. 
 (u) Application of
Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of
the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of
the Securities. 
 (v) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth
in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the Securities Act. 

(w) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to
which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, and (iii) has set aside on its books
provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. 

(x) No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the
Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

 (y) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political
activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by
the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA. 

  
 13 

 (z) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the
Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department. 

(aa) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
“Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company or any Subsidiary, threatened. 
 (bb) Acknowledgment Regarding Purchasers’ Purchase of
Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company
further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any
Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further
represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its
representatives. 
 (cc) Related Party Transactions. Except as set forth on Schedule 3.1(cc), no employee, officer, or director of the
Company (a “Related Party”) or member of such Related Party’s immediate family, or any corporation, partnership or other entity in which such Related Party is an officer, director or partner, or in which such Related Party has
significant ownership interests or otherwise controls, is indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. None of such persons has any direct or indirect ownership
interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation that competes with the Company, except that employees, officers, or directors of the Company
and members of such Related Party’s immediate families may own stock in but not exceeding 2% of the outstanding capital stock of) publicly traded companies that may compete with the Company. No Related Party or member of their immediate family
is directly or indirectly interested in any material contract with the Company. 
 (dd) Regulatory. The Company has such permits, licenses,
certificates, approvals, 

  
 14 

 
clearances, authorizations or amendments thereto (the “Regulatory Permits”) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies necessary to conduct
the business of the Company; including, without limitation, any Investigational New Drug Application as required by the U.S. Food and Drug Administration or other authorizations issued by federal, state, local or foreign agencies or bodies engaged
in the regulation of pharmaceuticals such as those being developed by the Company, except for any of the foregoing that would not, individually or in the aggregate, have a Material Adverse Effect. The Company is in compliance in all material
respects with the requirements of the Regulatory Permits, and all of the Regulatory Permits are valid and in full force and effect, in each case in all material respects; the Company has not received any notice of proceedings relating to the
revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would not have a Material Adverse Effect. 

(ee) No Disqualification Events. No “Bad Actor” disqualifying event described in Rule 506(d)(1)(i) to (viii) of the Securities
Act (a “Disqualification Event”) is applicable to the Company, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable. 

(ff) Disclosure. All disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company, its business and the
transactions contemplated hereby, including the Disclosure Schedules, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2. 
 3.2 Representations and Warranties of the
Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof, and as of each Closing Date in which such Purchaser is participating hereunder, to the Company as follows (unless as of a
specific date therein): 
 (a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or
formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the
transactions contemplated by this Agreement and each of the other applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.
This Agreement and each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof and thereof, will constitute the valid and legally binding
obligation of such Purchaser, 

  
 15 

 
enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law. 
 (b) Own Account. Such Purchaser understands that the
Securities are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing
or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state
securities law and has no direct or indirect arrangement or understanding with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this
representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). 

(c) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, an
“accredited investor” as defined in Rule 501 under the Securities Act. 
 (d) Experience of Such Purchaser. Such Purchaser,
either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so
evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 

(e) General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement. 

(f) Reliance on Exemptions. Such Purchaser understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. 

(g) Information. Such Purchaser and its advisors, if any, have been furnished with copies of due diligence materials relating to the
business, finances and operations of the Company 

  
 16 

 
and materials relating to the offer and sale of the Securities, which have been requested by such Purchaser. Such Purchaser and its advisors, if any, have been afforded the opportunity to ask
questions of the Company regarding the terms and conditions of the transaction contemplated by this Agreement. 
 (h) No Governmental
Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the
investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 
 (i)
Transfer or Resale. Such Purchaser understands that, except as provided in the Registration Rights Agreement: (i) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may
not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Purchaser shall have delivered to the Company (if reasonably requested by the Company) an opinion of counsel to such Purchaser,
in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Purchaser provides the
Company with reasonable assurance (as evidenced by a certificate of such Purchaser, if requested by the Company) that such Securities can be sold, assigned or transferred pursuant to Rule 144; (ii) any sale of the Securities made in reliance on
Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the Commission promulgated thereunder; and (iii) neither the Company nor any other
Person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder except pursuant to the Registration Rights Agreement. 

(j) No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and each of the applicable Transaction
Documents to which such Purchaser is a party and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) conflict
with, or constitute a default (or an event that with or without notice, lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time
or both) of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the
ability of such Purchaser to perform its obligations hereunder. 

  
 17 

 (k) No Consents Required. No application, notice, order, registration, qualification,
waiver, consent, approval or other action is required to be filed, given, obtained or taken by such Purchaser by virtue of the execution, delivery and performance of this Agreement and each of the Transaction Documents to which such Purchaser is a
party or the consummation of the transactions contemplated hereby and thereby, which has not already been obtained. 
 (l) Brokers and
Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company, any of its Subsidiaries or any Purchaser for any placement agent’s
fees, financial advisory fees, broker’s commissions or other similar compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Purchaser. 

ARTICLE IV. 
 OTHER
AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions. 

(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to
provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser
under this Agreement. 
 (b) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on
any of the Securities in the following form: 
 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY 

  
 18 

 
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN
RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. 
 The Company acknowledges and agrees that a Purchaser may
from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule
501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a
pledge would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection with any such pledge; provided, however, that any transfer of title to the pledgee
shall require an opinion of the pledgor’s or pledgee’s counsel that such transfer is permissible under applicable securities laws. Further, no notice shall be required of such pledge. At the appropriate Purchaser’s expense, the
Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities. 

(c) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in
compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company’s
reliance upon this understanding. 
 4.2 Integration. The Company shall not sell, offer for sale or solicit offers to buy or
otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the
sale of the Securities. 
 4.3 Publicity. The Company and each Purchaser shall consult with each other in issuing any press releases
with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press
release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the
disclosing party shall promptly provide the other party with prior notice of such public statement or communication. 
 4.4 Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an “Acquiring Person” under 

  
 19 

 
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.

 4.5 Non-Public Information. The Company covenants and agrees that from and after the time that the Company becomes subject to the
reporting requirements of Section 13 or 15(d) under the Exchange Act, neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. 
 4.6 Indemnification. 

(a) Subject to the provisions of this Section 4.6(a), the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all actual losses, liabilities, obligations, claims,
contingencies, damages, costs and expenses (other than consequential damages), including all judgments, amounts paid in settlements, court costs and reasonable and documented attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents (unless such action is based upon a
breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes
fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in
writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel, or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the
position of the Company and the position of such Purchaser Party, 

  
 20 

 
in which case the Company shall be responsible for the reasonable and documented fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party
under this Agreement for any settlement by a Purchaser Party effected without the Company’s prior written consent. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party
against the Company or others and any liabilities the Company may be subject to pursuant to law. 
 (b) Subject to the provisions of this
Section 4.6(b), each Purchaser, jointly and severally, will indemnify and hold the Company and its directors, officers, shareholders, employees and agents (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title), each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a
“Company Party”) harmless from any and all actual losses, liabilities, obligations, claims, contingencies, damages, costs and expenses (other than consequential damages), including all judgments, amounts paid in settlements, court
costs and reasonable and documented attorneys’ fees and costs of investigation that any such Company Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by
the Company in this Agreement or in the other Transaction Documents (unless such action is based upon a breach of the Company’s representations, warranties or covenants under the Transaction Documents or any violations by a Company Party of
state or federal securities laws or any conduct by such Company Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Company Party in respect of which indemnity may be sought
pursuant to this Agreement, such Company Party shall promptly notify each Purchaser in writing, and the Purchasers shall have the right to assume the defense thereof with counsel of their own choosing reasonably acceptable to the Company Party. Any
Company Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Company Party except to the extent that (i) the
employment thereof has been specifically authorized by the Purchasers in writing, (ii) the Purchasers have failed after a reasonable period of time to assume such defense and to employ counsel, or (iii) in such action there is, in the
reasonable opinion of counsel, a material conflict on any material issue between the position of the Purchasers and the position of such Company Party, in which case the Purchasers shall be responsible for the reasonable and documented fees and
expenses of no more than one such separate counsel. The Purchasers will not be liable to any Company Party under this Agreement for any settlement by a Company Party effected without the Purchasers’ prior written consent. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Company Party against the Purchasers or others and any liabilities the Purchasers may be subject to pursuant to law. 

4.7 Listing of Securities. In connection with the consummation of an initial public offering of the Company, the Company shall
(i) take all steps necessary to cause such Securities to be approved for listing or quotation on such Trading Market and (ii) provide to the Purchasers evidence of such listing or quotation. 

  
 21 

 4.8 Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to
the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to
qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser. 

ARTICLE V. 

MISCELLANEOUS 
 5.1
Termination. This Agreement may be terminated by any party hereto, as to such party’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the
other parties, if the Initial Closing has not been consummated on or before [December 31], 2014; provided, however, that such termination will not affect the right of any party to sue for any breach by any other party (or parties).

 5.2 Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any,
and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for
same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes and duties levied in connection with the sale and delivery of any Securities to the Purchasers. 

5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into
such documents, exhibits and schedules. 
 5.4 Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the
signature pages attached hereto at or prior to 5:30 p.m. (California time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (California time) on any Trading Day, (c) the second (2nd) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the
signature pages attached hereto. 

  
 22 

 5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least [50.1]% in interest of the Securities then outstanding or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. 

5.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. 
 5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit
of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). 

5.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and
permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.6 and this Section 5.8. 

5.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners,
members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of San Diego, State of California. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of San Diego, State of California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the
Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or
is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or 

  
 23 

 
proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company and the Purchasers under Section 4.6, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 

5.10 Survival. The representations and warranties contained herein shall survive the Initial Closing and all Additional Closings and
the delivery of the Securities. 
 5.11 Execution. This Agreement may be executed in two or more counterparts, all of which when
taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In
the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 
 5.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set
forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or
substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 
 5.13 Rescission and
Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a
Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any
relevant notice, demand or election in whole or in part without prejudice to its future actions and rights. 
 5.14 Replacement of
Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of
mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. 

  
 24 

 5.15 Remedies. In addition to being entitled to exercise all rights provided herein or
granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss
incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or
equitable cause of action), then, to the extent of any such restoration, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred. 
 5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of
each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser
under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be
entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose. 
 5.18 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. 

5.19 Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar
transactions of the Common Stock that occur after the date of this Agreement. 

  
 25 

 5.20 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY
JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 (Signature Pages Follow) 

  
 26 

 SORRENTO COMMENTS 12/9/14 

IN WITNESS WHEREOF, the parties hereto have caused this Subscription and Investment Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above. 
  

							
	CONKWEST, INC.	  		  	 Address for Notice:
 2533 South Coast
Highway 101, Suite 210
 Cardiff by the Sea, CA 92007

	By:	  	  
	  		  	Fax: 858-380-1999
		  	 Name: Barry Simon
 Title:   Chief
Executive Officer
	  		  	
			
	With a copy to (which shall not constitute notice):	  		  	
			
	 Anthony J. Marsico, Esq.
 Greenberg
Traurig, LLP
 The MetLife Building
 200 Park Avenue

New York, NY 10166
	  		  	

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 

SIGNATURE PAGE FOR PURCHASER FOLLOWS] 

  
 [Signature Page
to Stock Purchase Agreement] 

 [PURCHASER SIGNATURE PAGES TO CONKWEST SUBSCRIPTION AND INVESTMENT AGREEMENT] 

IN WITNESS WHEREOF, the undersigned have caused this Subscription and Investment Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above. 
 Name of Purchaser: Sorrento Therapeutics, Inc. 

 

			
	Signature of Authorized Signatory of Purchaser:	 	  

			
		
	Name of Authorized Signatory:	 	  

			
		
	Title of Authorized Signatory:	 	  

			
		
	Email Address of Authorized Signatory:	 	  

 Facsimile Number of Authorized Signatory: 858-210-3759 

Jurisdiction of Organization: Delaware 
 Address for Notice to
Purchaser: 
 6042 Cornerstone Ct. West, Suite B 
 San Diego, CA
92121 
 With a copy to (which shall not constitute notice): 

Jeffrey T. Hartlin, Esq. 
 Paul Hastings LLP 

1117 S. California Avenue 
 Palo Alto, CA 94304 

Address for Delivery of Securities to Purchaser (if not same as address for notice): 

Subscription Amount of Common Stock at Initial Closing: $1,000,000.00 

Subscription Amount of Common Stock at First Additional Closing: $1,000,000.00 (or more, if approved by Sorrento Therapeutics, Inc. and agreed to in writing
by Conkwest, Inc.) 
 Subscription Amount of Common Stock at Second Additional Closing: $1,000,000.00 

EIN Number: 33-0344842 

  
 [Signature Page
to Stock Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]